Kind 8-Okay PROKIDNEY CORP. For: Nov 28

Kind 8-Okay PROKIDNEY CORP. For: Nov 28

[ad_1]

November 30, 2023 6:59 AM EST

false 0001850270 0001850270 2023-11-28 2023-11-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-Okay

CURRENT REPORT

Pursuant to Part 13 or 15(d)

of the Securities Trade Act of 1934

Date of Report (Date of earliest occasion reported): November 28, 2023

PROKIDNEY CORP.

(Precise title of Registrant as Laid out in Its Constitution)

Cayman Islands 001-40560 98-1586514

(State or Different Jurisdiction

of Incorporation)

(Fee

File Quantity)

(IRS Employer

Identification No.)

2000 Frontis Plaza Blvd.
Suite 250
Winston-Salem, North Carolina 27103
(Deal with of Principal Government Places of work) (Zip Code)

Registrant’s Phone Quantity, Together with Space Code: 336 999-7029

(Former Identify or Former Deal with, if Modified Since Final Report)

Examine the suitable field beneath if the Kind 8-Okay submitting is meant to concurrently fulfill the submitting obligation of the registrant beneath any of the next provisions:

Written communications pursuant to Rule 425 beneath the Securities Act (17 CFR 230.425)

Soliciting materials pursuant to Rule 14a-12 beneath the Trade Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) beneath the Trade Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) beneath the Trade Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Part 12(b) of the Act:

Title of every class

Buying and selling

Image(s)

Identify of every alternate

on which registered

Class A extraordinary shares, $0.0001 par worth per share PROC The Nasdaq Inventory Market

Point out by test mark whether or not the registrant is an rising development firm as outlined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Trade Act of 1934 (§ 240.12b-2 of this chapter).

Rising development firm

If an rising development firm, point out by test mark if the registrant has elected to not use the prolonged transition interval for complying with any new or revised monetary accounting requirements supplied pursuant to Part 13(a) of the Trade Act.


Merchandise 5.02

Departure of Administrators or Sure Officers; Election of Administrators; Appointment of Sure Officers; Compensatory Preparations of Sure Officers.

On November 28, 2023, ProKidney Corp. (“ProKidney” or the “Firm”) notified Deepak Jain, Ph.D., Chief Working Officer of the Firm, of the termination of his employment with out trigger, efficient as of the identical date, following which Dr. Jain is anticipated to proceed to function a guide to the Firm. The Firm expects to enter right into a separation settlement with Dr. Jain, the phrases of which can be disclosed as soon as accessible. ProKidney expresses its gratitude to Dr. Jain for his nearly twenty years of scientific and working management to deliver the Firm’s Renal Autologous Cell Remedy (REACT®) product candidate from pre-clinical and early medical growth into Part 3.


SIGNATURES

Pursuant to the necessities of the Securities Trade Act of 1934, the registrant has duly brought on this report back to be signed on its behalf by the undersigned hereunto duly approved.

PROKIDNEY CORP.
Date: November 30, 2023 By:

/s/ Todd Girolamo

Identify: Todd Girolamo
Title: Chief Authorized Officer

ATTACHMENTS / EXHIBITS

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

IDEA: R1.htm

IDEA: d471267d8k_htm.xml

IDEA: Financial_Report.xlsx

IDEA: FilingSummary.xml

IDEA: MetaLinks.json


Severe Information for Severe Merchants! Strive StreetInsider.com Premium Free!


You Could Additionally Be In


You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *